List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Optic Neuropathy - Overview
Optic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuropathy - Companies Involved in Therapeutics Development
Allergan Plc
Antoxis Ltd
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
Optic Neuropathy - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimonidine tartrate implant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSIC-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELN-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fab-3H4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPh-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dominant Optic Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuropathy - Dormant Projects
Optic Neuropathy - Discontinued Products
Optic Neuropathy - Product Development Milestones
Featured News & Press Releases
May 14, 2019: Regenera announces publication of RPh201 Phase 2a study data for the treatment of NAION in the Journal of Neuro-Ophthalmology
Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting
Aug 06, 2018: Regenera Pharma enrols first patient in Phase lll trial of RPh201
Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007
Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’
Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007
Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Optic Neuropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Optic Neuropathy - Pipeline by Allergan Plc, H1 2020
Optic Neuropathy - Pipeline by Antoxis Ltd, H1 2020
Optic Neuropathy - Pipeline by Neurizon Pharma GBR, H1 2020
Optic Neuropathy - Pipeline by PharmatrophiX Inc, H1 2020
Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H1 2020
Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Optic Neuropathy - Dormant Projects, H1 2020
Optic Neuropathy - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Optic Neuropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

Companies Mentioned
• Allergan Plc
• Antoxis Ltd
• Neurizon Pharma GBR
• PharmatrophiX Inc
• Quark Pharmaceuticals Inc
• Recursion Pharmaceuticals Inc
• Regenera Pharma Ltd
• Regeneron Pharmaceuticals Inc